Intravitreal bevacizumab treatment for severe retinopathy of prematurity

Intravitreal bevacizumab treatment for severe retinopathy of prematurity - Intravitreal bevacizumab treatment for severe retinopathy of prematurity

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018122

Enrollment

Registered

2015-06-29

Start date

2012-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

severe retinopathy of prematurity

Interventions

Patients with severe retinopathy of prematurity which were ineffective by laser therapy.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with severe retinopathy of prematurity which were ineffective by laser therapy.

Exclusion criteria

Exclusion criteria: Patients with retinopathy of prematurity which are treatable by laser therapy.

Design outcomes

Primary

Measure	Time frame
Regress the retinopathy of prematurity	—

Countries

Japan

Contacts

Public ContactYasuhiro Ohkuma

The Jikei University School of Medicine Ophthalmology

yookuma1110@gmail.com03-3433-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026